Prostate cancer screening outreach: shared decision pages, PSA claims, Medicare coverage, recall texts and free PSA events

Prostate cancer screening outreach is different from other cancer screening outreach. The federal recommendation does not tell men aged 55 to 69 to get a PSA test; it tells them to decide, with a clinician, after hearing the possible benefits and harms. A campaign that pushes every man toward a test, or that promises the test will save his life, goes past what the federal sources say. The program may be a primary care office that adds the conversation to its recall list, a urology practice, a men’s health clinic, a community health center, a health fair, or a church or barbershop event. This guide covers how to build a screening page on the shared decision the USPSTF describes, how to word claims about the PSA test and newer tests, how to explain coverage when Medicare and private plans treat the test differently, how to word recall texts and results calls, and how free PSA events and partners meet the federal rules.

Seven related topics have their own guides and are not repeated here. Urology practices are covered in our guide to urology practice marketing and men’s health clinics in our guide to men’s health clinic marketing. Screening events are covered in our guide to health fair and screening event marketing. Other cancer screening programs are covered in our guides to lung cancer screening marketing, colorectal cancer screening outreach and cervical cancer screening and HPV vaccine outreach, and Medicare visits that can carry the conversation in our guide to annual wellness visit outreach.

What the federal sources say

The US Preventive Services Task Force (USPSTF), the CDC, the National Cancer Institute (NCI), MedlinePlus from the National Library of Medicine and Medicare.gov publish the federal positions on prostate cancer screening. The points that shape an outreach program’s marketing:

• The USPSTF final recommendation Prostate Cancer: Screening (May 8, 2018) says that for men aged 55 to 69 the decision to undergo periodic prostate-specific antigen (PSA) based screening should be an individual one, a grade C recommendation, and that before deciding, men should have an opportunity to discuss the potential benefits and harms with their clinician. It recommends against PSA-based screening for men 70 and older, a grade D recommendation. It says clinicians should not screen men who do not express a preference for screening.
• The same USPSTF recommendation names older age, African American race and a family history of prostate cancer as the leading risk factors, says there is inadequate evidence to assess whether the benefits for African American men and men with a family history differ from those for the average-risk population, and suggests clinicians inform men with a family history about their increased risk. It does not recommend the digital rectal exam (DRE) as a screening test.
• The CDC page Screening for Prostate Cancer (updated September 1, 2026, read through an archived copy) says there is no standard test to screen for prostate cancer, that the main screening test is the PSA blood test, that conditions other than cancer can raise the PSA level, that an abnormal result may lead the doctor to recommend a biopsy, and that other organizations may have other recommendations.
• The NCI page Prostate-Specific Antigen (PSA) Test (updated January 31, 2025) says there is no single threshold that distinguishes a normal from an abnormal PSA result, explains overdiagnosis and overtreatment, and says about 6 to 7 percent of men have a false-positive PSA test on any given screening round and only about 25 percent of men who have a biopsy due to an elevated PSA level are found to have prostate cancer.
• The NCI summary Prostate Cancer Screening (PDQ), Patient Version (updated December 10, 2024) and the MedlinePlus page Prostate Cancer Screening (last updated August 23, 2024) explain the tests and the risks of screening in plain words and can be linked from a practice page as reading for the decision.
• The Medicare.gov page Prostate cancer screenings, checked on October 30, 2026, says Part B covers digital rectal exams and PSA blood tests once every 12 months for men over 50, starting the day after the 50th birthday.

The USPSTF recommendation is more than eight years old. Its own page is marked as an update in progress, and the USPSTF Recommendations in Progress page, checked on October 30, 2026, lists Prostate Cancer: Screening at the stage of developing the draft recommendation statement. Name the 2018 recommendation and its date next to the ages it gives, say that a clinician helps each man decide, and check the USPSTF site at each review so the page changes when a draft or a final update appears.

We also checked FDA’s records for the tests themselves, because a page about a newer test can drift into claims the test’s approval does not support. FDA’s device classification database lists PSA tests for the detection of prostate cancer as class III devices, which go through premarket approval, and our check of the FDA premarket approval database on October 30, 2026 found newer approvals, including a test approved in November 2025 that combines PSA measurements into a single index. Describe any test by what it measures and by the use its approved labeling states, and name no brand.

Two points shape the marketing. First, the federal recommendation is a decision, not an instruction: the message is “talk with us about whether a PSA test is right for you”, not “get tested”. Second, coverage and recommendation are separate. Medicare covers a yearly PSA test from just after age 50 with no age limit stated on its page, while the USPSTF recommends against screening at 70 and older; a page that reads “Medicare covers it, so you should have it” mixes the two.

Screening pages and claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “prostate cancer screening guidelines”, “prostate cancer screening age”, “prostate cancer screening uspstf”, “prostate cancer screening test” and “prostate cancer screening blood test” to a person who types “prostate cancer screening”, “psa test meaning”, “psa test results”, “psa test normal range”, “psa test preparation” and “psa test price” after “psa test”, “prostate exam age” and “prostate exam procedure” after “prostate exam”, “prostate cancer screening age with family history” after “prostate cancer screening age”, and “free psa screening near me” and “free prostate exam near me” after “free prostate screening”. A screening page can answer each of those honestly: who the decision is for and at what age, what the PSA test is and what a result can and cannot tell, how family history and race change the conversation, what the exam involves, and what the test costs and who pays.

A page that holds up says that the PSA test is a blood test, that the federal recommendation asks men aged 55 to 69 to decide with a clinician, that the visit includes time to talk through the possible benefits and harms, and that a man can decide not to be tested. It names the clinician or role who has the conversation, explains how results are given and what may happen after a raised result, and links the NCI or MedlinePlus pages for reading before the visit. It offers the page in the languages the practice’s patients speak.

Phrases that need rewriting:

• “Every man over 50 needs a PSA test every year.” The USPSTF asks men aged 55 to 69 to decide with a clinician and recommends against screening at 70 and older. Name the source and its ages, and say the clinician and the patient decide together.
• “Catch it early saves lives.” Use this only as a quote from a named source. NCI says the potential benefit is that the test may help detect prostate cancer earlier, and also lists overdiagnosis, overtreatment and false-positive results. Quote NCI’s own wording on both sides, with the date.
• “A normal PSA means you don’t have cancer.” NCI says there is no single threshold that separates a normal from an abnormal result. Say a clinician explains each result and what comes next.
• “A high PSA means cancer.” CDC says conditions that are not cancer can raise the PSA level. Say a raised result leads to a conversation about the next step, which may be a repeat test or other tests.
• “Our new test means you’ll never need a biopsy.” Describe a newer test by what its approved labeling says it does, confirmed with the lab, and say the clinician decides what is needed. Name no brand.
• “Our screening program has found hundreds of cancers.” Outcome numbers with no source. Remove them unless they are drawn from the practice’s own documented and reviewed records, with their date and limits stated, and even then counts of cancers found do not show benefit, as the NCI page on overdiagnosis explains.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. Quoting the federal sources as written, with each one named and dated, stays inside that standard; turning a federal statement into a promise to the reader does not.

Symptoms, urgent signs and 911 on every page and in every tool

Screening is for men without symptoms, so the page has to send men with symptoms elsewhere. The CDC page Symptoms of Prostate Cancer (updated September 1, 2026, read through an archived copy) says early prostate cancer may cause no symptoms, lists difficulty starting urination, needing to urinate again and again, especially at night, pain or burning during urination, blood in the urine or semen, pain in the back, hips or pelvis that doesn’t go away, and painful ejaculation, tells people with these symptoms to see a doctor right away, and notes that conditions that are not cancer, such as an enlarged prostate, can cause them. Put plain lines above the booking button and on flyers: if you have any of these symptoms, call [phone] and ask for a visit; do not wait for a screening appointment. Call 911 for an emergency.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools, and on cards handed out at a screening event. A tool should hand any message about a symptom to a clinician or the on-call line, send any message about an emergency to the 911 line and alert staff, pass questions about results to a clinician, and never explain a PSA result itself. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Building the shared decision into the page and the visit

The USPSTF says men aged 55 to 69 should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. The marketing has to leave room for that conversation, which means the booking path is for a talk about screening, not for a test. Keep these points:

• Name the booking option “Talk about prostate cancer screening” or similar, not “Book your PSA test”, and say the man can decide not to have the test.
• Give both sides in the federal words: NCI’s description of the potential benefit, and its description of false-positive results, overdiagnosis and overtreatment, each with the date.
• Link the NCI PDQ patient summary or the MedlinePlus page for reading before the visit, and if the practice uses a decision aid, say who made it and when it was last reviewed.
• For men 70 and older, do not run screening ads or recall messages. A man of that age who asks can talk with his clinician, and the page can say the USPSTF recommends against routine screening at that age and why, in its words.
• For men younger than 55, do not set an age to start on the page. Say that men with a family history or other risk factors can ask their clinician when to talk about screening.

Family history and outreach to African American men

The “prostate cancer screening age with family history” search and community outreach to African American men need extra care, because the federal sources give no separate age or interval for these groups. The USPSTF names both as higher-risk groups, says the evidence is inadequate to assess whether the benefits differ for them, and suggests that clinicians inform men with a family history of their increased risk. Keep these points:

• Say the higher risk in the USPSTF’s words, with the date, and invite these men to talk with a clinician about screening; do not give them a different starting age on the page unless it quotes a named source that sets one.
• Plan community events with the community: work with local leaders, hold events in places men already trust, and have a clinician available to answer questions, not just a table that draws blood.
• Avoid wording that blames a group, uses fear or implies men who did not get tested are irresponsible. Lead with the choice and the information.
• For men with a strong family history, inherited risk and genetic counseling follow our guide to genetic testing marketing.

Supplements offered for prostate health need the same care. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product, make no claim that a supplement lowers PSA, shrinks the prostate or prevents prostate cancer, and follow our guide to selling supplements in a medical practice.

Results calls and what comes after a raised PSA

The NCI PSA page says that after an abnormal result the doctor may recommend another PSA test in 6 to 8 weeks to confirm it, or a biopsy, that newer blood and urine tests may help decide whether a biopsy is needed, and that an MRI may guide a biopsy when imaging shows a suspicious area. A results page or a results message can set expectations without explaining anyone’s own result. Keep these points:

• Say how and when the practice calls with results and who explains them. Never post, text or leave the result on voicemail.
• Say that a raised PSA can have causes other than cancer, as CDC and NCI say, and that the clinician explains the next step, which may be a repeat test, other tests or a referral.
• Do not describe a biopsy, imaging or a newer test as painless or risk free; NCI lists pain, bleeding and infection among the possible harms of a biopsy.
• If the practice refers men to a urologist for follow-up, say so on the page and follow our guide to patient and physician referrals.

Recall texts, letters and reminders

Outreach programs reach men through recall lists: men aged 55 to 69 with no screening conversation on file, and men with a raised result who have not come back for the repeat test or follow-up. Under 45 CFR 164.501, a communication about the practice’s own treatment for an individual, such as a reminder to come in for a recommended visit or a follow-up test, can fall outside the definition of marketing, while a message that promotes a third party’s product or service generally needs a signed authorization under 45 CFR 164.508.

The words in the message matter as much as the rule. A text, a postcard or a voicemail can be seen by a partner or a family member. Keep these points:

• Name no test, no result and no body part in the message text. Write “[Practice name]: it is time for a visit with your clinician. Call [phone] or book online.” and give details only after the man signs in or calls.
• A follow-up reminder can say “Please call [phone] to schedule your follow-up visit.” without naming the result.
• Do not mention the prostate, PSA or cancer on an envelope, a postcard or a caller ID name, and do not leave a result on voicemail.
• Do not build recall lists from men 70 and older for screening, and stop screening reminders for a man who has decided, with his clinician, not to be screened.
• Send messages in the language the patient chose, use the contact method he chose, and honor opt-out requests in every channel.
• Do not send recall lists or results to an ad platform to build an audience.

Our guides to text message appointment reminders and the patient recall system cover consent, timing and opt-outs.

Free PSA events, coverage and costs

Coverage pages draw the “psa test price” and “free psa screening near me” searches. The Medicare.gov page says that for the PSA blood test the person pays nothing, and that for the digital rectal exam the person pays 20 percent of the Medicare-approved amount after the Part B deductible, with a separate copayment in a hospital outpatient setting. It also says a provider who does not accept assignment may charge an added fee for the doctor’s services, but not for the test itself. Describe Medicare coverage in those terms and say the practice checks coverage for each patient.

Private plans are a separate question. Under 42 U.S.C. 300gg-13, group health plans and health insurers must cover, without cost sharing, evidence-based items or services that have a rating of “A” or “B” in the current USPSTF recommendations. The USPSTF prostate recommendation is a grade C, so that rule does not by itself require no-cost coverage of PSA screening; a plan may still cover it. CDC’s screening page tells people to check with their plan. Do not write “covered by all insurance” or “free under the ACA”; say the practice checks coverage before the visit. Cash prices for a PSA test follow our guides to advertising cash prices and good faith estimates for self-pay patients, and Medicare messaging follows our guide to marketing to Medicare patients.

A free PSA day at a health fair, church or workplace carries both the shared decision and the free offer rules. Have a clinician or trained staff member explain the possible benefits and harms before anyone has blood drawn, record that the man chose the test, and arrange in advance who calls each man with the result and who arranges follow-up for a raised result, including men with no regular doctor. Do not draw blood at an event without a plan for results and follow-up.

A “free” PSA test, a free exam or a gift card for coming in follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and that the terms of the offer should be stated at the outset. Under 42 U.S.C. 1320a-7a(a)(5), civil penalties can apply to a person who offers or transfers remuneration to a Medicare or state health care program beneficiary that the person knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider, practitioner or supplier. Free tests and incentives at events need counsel’s review before they run, and a grant-funded program should also check its grant terms.

Partners, sponsors and referral payments

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state.

For a prostate cancer screening program, keep these points:

• Do not accept free staff, free tests, event funding or marketing help from a lab, a test maker, an imaging center or a treatment center tied to the tests and referrals that follow, without counsel’s review; our guide to Open Payments covers reported payments from manufacturers.
• Do not steer samples to one lab, or men with a raised result to one imaging center or urology group, in exchange for anything of value.
• Do not pay a church, a barbershop, an employer, a community group, an outreach worker or a marketing company per man tested or referred without counsel’s review.

Privacy, pixels and ads

A visit to a PSA page, a results question or a booking form says something about a man’s health. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place, language settings and search terms, should not be aimed at men 70 and older for screening, and should not be built from a list of patients or men who were tested.

Tone and patient stories

Men may put off the conversation because of embarrassment about the exam, worry about the result, or fear of treatment side effects. Lead with what the test is and that the visit starts with a talk, say the PSA test is a blood test, say the man can ask questions and decide, and keep fear out of it: no countdowns, no images of illness, no wording that suggests a man who has not been tested is failing his family. Use person-first words, and include transgender women and nonbinary people who have a prostate where the source allows, while keeping the source’s own wording when you quote it.

A story from a man who talked through the decision, or a family member who encouraged the conversation, can carry the message. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. A story of a cancer found by a PSA test is exactly that kind of claim, and NCI’s description of overdiagnosis shows why it does not stand for others. Pair the story with the attributed federal statement, say results differ, and get a signed authorization under 45 CFR 164.508 where the practice is a covered entity. A story should not name a result or a diagnosis unless the man chose to share it in writing, and should name no test brand; say if the person received anything for taking part, and let him review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two prostate screening outreach messages

Illustration: a flyer reads “Men over 50: get your PSA every year, no excuses. Catch it early, it saves lives. A normal PSA means you’re cancer free. Medicare pays, so there’s no reason to wait, whatever your age. Free PSA and a free gift card at Saturday’s event!” It tells every man to test, uses a slogan as fact, misstates what a normal result means, mixes Medicare coverage with a recommendation and invites men 70 and older, and offers a gift card without counsel’s review.

Illustration: a second flyer for the same practice reads “Prostate cancer screening is a choice. Federal recommendations ask men aged 55 to 69 to decide about the PSA blood test with their clinician, after hearing the possible benefits and harms. At [Practice name], [Clinician name, license] will talk it through with you, and you decide. Higher risk because of family history? Ask us when to talk about it. Trouble urinating, blood in your urine or semen, or pain that doesn’t go away? Call [phone] for a visit, do not wait for screening. Call 911 for an emergency. Call [phone] during [days and hours] to book a conversation.” It names the federal age range, leaves the decision to the man and his clinician, avoids fear and promises, and puts the symptom and emergency lines first.

Checklist before a prostate cancer screening campaign goes live

• Screening copy built on the USPSTF 2018 recommendation, named and dated, with its grade C shared decision for ages 55 to 69 and its recommendation against screening at 70 and older, and the USPSTF site checked for a draft or final update at each review.
• The booking path is for a conversation, not a test; the page says the man can decide not to be tested; NCI or MedlinePlus pages linked for reading.
• Both benefits and harms given in NCI’s words with the date; no slogan stated as fact; no claim that a normal result rules out cancer or that a high result means cancer.
• Newer tests described by their approved use as confirmed with the lab, with no brand names and no promise to avoid a biopsy.
• Family history and outreach to African American men worded as the USPSTF words them; no separate starting age unless a named source sets one; events planned with the community.
• The symptom line and the 911 line on pages, flyers, event cards, voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools, reviewed by the practice’s clinicians.
• Recall texts, postcards, caller ID names and voicemails name no test, result or body part; no screening recall to men 70 and older or men who decided against it; opt-outs honored.
• Medicare coverage described as Medicare.gov states it; private plan coverage checked per patient, with no “free under the ACA” claim for a grade C service.
• Free PSA events with a talk before the blood draw, a results plan and a follow-up plan; free tests and gift cards reviewed by counsel under 16 CFR 251.1 and 42 U.S.C. 1320a-7a(a)(5).
• No free staff, tests or funding from labs, test makers, imaging centers or treatment centers tied to orders and referrals, and no per-man payments to partners or venues, without counsel’s review.
• Form answers, bookings and patient lists stay out of pixels and ad audiences; stories have signed authorizations and say results differ.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including primary care, urology, men’s health and community health practices. For a prostate cancer screening program, that means a site that builds its screening page on the USPSTF shared decision as written and dated, gives the benefits and harms in the words NCI uses, explains Medicare and plan coverage without a promise, puts the symptom and 911 lines above the booking button, and answers “prostate cancer screening age” and “psa test results” searches honestly, plus appointment request pages that book a conversation and keep answers off the web and away from tracking tools. Our front desk tools hand symptoms to a clinician or the on-call line, emergencies to the 911 line, and questions about results to a clinician, and do not explain test results. We do not decide who should be screened or which test to use; your clinicians and patients do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• USPSTF: Prostate Cancer: Screening (final recommendation, May 8, 2018; update in progress)
• USPSTF: Recommendations in Progress (checked October 30, 2026)
• CDC: Screening for Prostate Cancer (updated September 1, 2026)
• CDC: Symptoms of Prostate Cancer (updated September 1, 2026)
• National Cancer Institute: Prostate-Specific Antigen (PSA) Test (updated January 31, 2025)
• National Cancer Institute: Prostate Cancer Screening (PDQ), Patient Version (updated December 10, 2024)
• MedlinePlus: Prostate Cancer Screening (last updated August 23, 2024)
• Medicare.gov: Prostate cancer screenings (checked October 30, 2026)
• FDA: Product Classification database (checked October 30, 2026)
• FDA: Premarket Approval (PMA) database (checked October 30, 2026)
• 42 U.S.C. 300gg-13: Coverage of preventive health services
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7a: Civil monetary penalties
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing